Skip to main content

Aspergillosis

22
Pipeline Programs
9
Companies
16
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
8
3
5
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
8100%
+ 14 programs with unclassified modality

On Market (2)

Approved therapies currently available

Pfizer
VFENDApproved
voriconazole
Pfizer
Azole Antifungal [EPC]intravenous2002
10K Part D
Pfizer
VORICONAZOLEApproved
voriconazole
Pfizer
Azole Antifungal [EPC]oral2016

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
6 programs
2
1
2
anidulafungin and voriconazolePhase 4Small Molecule1 trial
voriconazolePhase 4Small Molecule1 trial
voriconazolePhase 3Small Molecule1 trial
Anidulafungin, VER002Phase 2/31 trial
VoriconazolePhase 2/3Small Molecule1 trial
+1 more programs
Active Trials
NCT04744454Completed94Est. Jan 2026
NCT00037206Completed30Est. Feb 2003
NCT00159822Completed48Est. Dec 2008
+3 more trials
Astellas
AstellasChina - Shenyang
5 programs
2
2
1
MicafunginPhase 41 trial
IsavuconazolePhase 3Small Molecule
isavuconazolePhase 3Small Molecule
FK463Phase 21 trial
MicafunginPhase 21 trial
Active Trials
NCT00036166Completed326Est. Jan 2002
NCT00047827Terminated2Est. Feb 2003
NCT02646800Terminated105Est. Dec 2014
MSD
MSDIreland - Ballydine
3 programs
2
1
PosaconazolePhase 3Small Molecule1 trial
MK0991, caspofungin acetatePhase 21 trial
caspofungin acetatePhase 21 trial
Active Trials
NCT00076869Completed55Est. Aug 2005
NCT00082524Completed50Est. Jul 2007
NCT02180165Completed116Est. Jan 2018
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
2
1
PosaconazolePhase 3Small Molecule
MK0991, caspofungin acetatePhase 2
caspofungin acetatePhase 2
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
nebulised liposomal amphotericin BPhase 2/3
Pulmocide
PulmocideUK - London
3 programs
1
2
PC945Phase 21 trial
PC945Phase 21 trial
PC945 - single dosesPhase 11 trial
Active Trials
NCT02715570Completed29Est. Apr 2018
NCT03870841Terminated4Est. Jun 2020
NCT03905447Terminated2Est. Jun 2020
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
nebulised liposomal amphotericin BPHASE_2_31 trial
Active Trials
NCT00263315Completed320Est. May 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasMicafungin
Pfizeranidulafungin and voriconazole
Pfizervoriconazole
MSDPosaconazole
Pfizervoriconazole
PfizerVoriconazole
PfizerAnidulafungin, VER002
Gilead Sciencesnebulised liposomal amphotericin B
PulmocidePC945
PulmocidePC945
MSDcaspofungin acetate
MSDMK0991, caspofungin acetate
AstellasMicafungin
AstellasFK463
PulmocidePC945 - single doses

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 1,670 patients across 16 trials

NCT02646800AstellasMicafungin

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

Start: Mar 2014Est. completion: Dec 2014105 patients
Phase 4Terminated
NCT00940017Pfizeranidulafungin and voriconazole

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Start: Sep 2008Est. completion: Oct 200824 patients
Phase 4Completed
NCT00620074Pfizervoriconazole

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Start: Aug 2008Est. completion: Feb 20096 patients
Phase 4Terminated
NCT02180165MSDPosaconazole

Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)

Start: Jul 2014Est. completion: Jan 2018116 patients
Phase 3Completed
NCT00531479Pfizervoriconazole

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Start: Jul 2008Est. completion: May 2011459 patients
Phase 3Completed
NCT00159822PfizerVoriconazole

Voriconazole For Chronic Bronchopulmonary Aspergillosis

Start: Jul 2005Est. completion: Dec 200848 patients
Phase 2/3Completed
NCT00037206PfizerAnidulafungin, VER002

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

Start: May 2002Est. completion: Feb 200330 patients
Phase 2/3Completed
NCT00263315Gilead Sciencesnebulised liposomal amphotericin B

Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis

Start: Jan 2000Est. completion: May 2006320 patients
Phase 2/3Completed
NCT03905447PulmocidePC945

The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.

Start: Sep 2019Est. completion: Jun 20202 patients
Phase 2Terminated
NCT03870841PulmocidePC945

The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

Start: Apr 2019Est. completion: Jun 20204 patients
Phase 2Terminated
NCT00082524MSDcaspofungin acetate

Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

Start: Apr 2004Est. completion: Jul 200750 patients
Phase 2Completed
NCT00076869MSDMK0991, caspofungin acetate

MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

Start: Jan 2003Est. completion: Aug 200555 patients
Phase 2Completed
NCT00047827AstellasMicafungin

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Start: Dec 2002Est. completion: Feb 20032 patients
Phase 2Terminated
NCT00036166AstellasFK463

Study of FK463 for the Treatment of Invasive Aspergillosis

Start: Jan 1999Est. completion: Jan 2002326 patients
Phase 2Completed
NCT02715570PulmocidePC945 - single doses

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

Start: Oct 2017Est. completion: Apr 201829 patients
Phase 1Completed
NCT04744454PfizerIsauvuconazole group

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Start: Oct 2021Est. completion: Jan 202694 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.